EUVIMEDOpdag EUVIMED
Crossref

Real‐World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps

Maaz S Haji iD, Abraham A Kassem iD, Alexa F Ibrahim iD, Paula V G Navarro iD, Deepthi Akella iD, Michele M Carr iD

Otolaryngology–Head and Neck Surgery · 2026-11-17

DOI: 10.1002/ohn.70523 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, published online on 2026-11-17. Written by Maaz S Haji and 5 co-authors. Institution: Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA. 17 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

To evaluate whether dupilumab initiation is associated with reduced short‐term flare burden, healthcare utilization, and surgical escalation in pediatric patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Study Design Retrospective cohort study.

Setting

TriNetX United States Collaborative Network.

Methods

Patients aged ≤18 years with chronic rhinosinusitis with nasal polyps were identified between January 1, 2015, and December 31, 2024. Dupilumab‐treated patients were indexed at treatment initiation and propensity score‐matched 1:1 to nondupilumab controls indexed at a systemic corticosteroid burst based on asthma, atopic dermatitis, allergic rhinitis, and prior endoscopic sinus surgery. Outcomes within 12 months were compared using risk ratios.

Results

In 442 matched patients (221 per cohort), dupilumab‐treated patients had lower rates of acute sinusitis (12/221 [5.4%] vs 31/221 [14.0%]; risk ratio [RR] 0.39; 95% CI: 0.20‐0.73; P = .002), systemic corticosteroid bursts (80/221 [36.2%] vs 101/221 [45.7%]; RR 0.79; 95% CI: 0.63‐0.99; P = .042), and functional endoscopic sinus surgery (19/221 [8.6%] vs 38/221 [17.2%]; RR 0.50; 95% CI: 0.30‐0.84; P = .007). Nasal polyp diagnoses were more frequently documented in the dupilumab‐treated cohort (148/221 [67.0%] vs 95/221 [43.0%]; P < .0001), while emergency department visits (16/221 [7.2%] vs 27/221 [12.2%]; P = .078) and inpatient admissions (12/221 [5.4%] vs 16/221 [7.2%]; P = .435) were similar between cohorts.

Conclusion

These findings suggest that dupilumab may be a steroid‐sparing and surgery‐sparing option in pediatric CRSwNP.

Subjects

Author keywords

CRSwNPTriNetXbiologic therapychronic rhinosinusitis with nasal polypsdupilumabfunctional endoscopic sinus surgeryotolaryngologypediatric otolaryngologysystemic corticosteroids

Authors and institutions

  • Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA.
  • Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
  • Department of Otolaryngology, University of Missouri School of Medicine, Columbia, Missouri, USA.

ORCID profiles: Maaz S Haji, Abraham A Kassem, Alexa F Ibrahim, Paula V G Navarro, Deepthi Akella, Michele M Carr

Cite

APA

Haji, M. S., Kassem, A. A., Ibrahim, A. F., Navarro, P. V. G., Akella, D., & Carr, M. M. (2026). Real‐World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70523

Vancouver

Haji MS, Kassem AA, Ibrahim AF, Navarro PVG, Akella D, Carr MM. Real‐World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70523

BibTeX
@article{Haji2026,
  author = {Haji, Maaz S and Kassem, Abraham A and Ibrahim, Alexa F and Navarro, Paula V G and Akella, Deepthi and Carr, Michele M},
  title = {Real‐World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2026},
  doi = {10.1002/ohn.70523}
}
Start for free →